Equities research analysts expect Eli Lilly and Co (NYSE:LLY) to report $5.47 billion in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Eli Lilly and’s earnings. The lowest sales estimate is $5.42 billion and the highest is $5.53 billion. Eli Lilly and posted sales of $5.23 billion during the same quarter last year, which would indicate a positive year over year growth rate of 4.6%. The business is expected to announce its next earnings results on Tuesday, April 24th.
According to Zacks, analysts expect that Eli Lilly and will report full year sales of $5.47 billion for the current year, with estimates ranging from $23.05 billion to $23.67 billion. For the next fiscal year, analysts expect that the firm will post sales of $23.84 billion per share, with estimates ranging from $23.30 billion to $24.17 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Eli Lilly and.
Eli Lilly and (NYSE:LLY) last released its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.06. The company had revenue of $6.16 billion during the quarter, compared to the consensus estimate of $5.93 billion. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. Eli Lilly and’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.95 EPS.
A number of analysts recently weighed in on LLY shares. Morgan Stanley boosted their target price on Eli Lilly and from $86.00 to $90.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 21st. BMO Capital Markets set a $73.00 target price on Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, December 5th. Credit Suisse Group restated a “hold” rating on shares of Eli Lilly and in a research report on Wednesday, December 13th. Argus upgraded Eli Lilly and from a “hold” rating to a “buy” rating and boosted their target price for the stock from $85.52 to $115.00 in a research report on Friday, January 5th. Finally, Goldman Sachs downgraded Eli Lilly and from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $86.98 to $95.00 in a research report on Tuesday, January 16th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $93.47.
Eli Lilly and (NYSE:LLY) traded up $1.74 during trading hours on Tuesday, reaching $80.49. The company had a trading volume of 8,326,275 shares, compared to its average volume of 5,103,736. The company has a market cap of $85,993.48, a P/E ratio of -402.43, a price-to-earnings-growth ratio of 1.46 and a beta of 0.28. Eli Lilly and has a one year low of $73.69 and a one year high of $89.09. The company has a quick ratio of 1.01, a current ratio of 1.32 and a debt-to-equity ratio of 0.85.
In other news, insider Donald A. Zakrowski sold 860 shares of the business’s stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $76.50, for a total transaction of $65,790.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $81.09, for a total value of $72,981.00. Following the transaction, the insider now directly owns 4,130 shares in the company, valued at $334,901.70. The disclosure for this sale can be found here. Insiders sold 12,261 shares of company stock valued at $987,485 in the last quarter. Corporate insiders own 0.20% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of LLY. Avestar Capital LLC purchased a new stake in Eli Lilly and in the fourth quarter worth $100,000. Gradient Investments LLC purchased a new stake in Eli Lilly and in the fourth quarter worth $103,000. MPS Loria Financial Planners LLC purchased a new stake in Eli Lilly and in the second quarter worth $128,000. San Francisco Sentry Investment Group CA purchased a new stake in Eli Lilly and in the second quarter worth $129,000. Finally, Front Row Advisors LLC purchased a new stake in Eli Lilly and in the fourth quarter worth $137,000. 77.58% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “$5.47 Billion in Sales Expected for Eli Lilly and Co (LLY) This Quarter” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/08/5-47-billion-in-sales-expected-for-eli-lilly-and-co-lly-this-quarter.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Get a free copy of the Zacks research report on Eli Lilly and (LLY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.